ジオクチルソジウムスルホサクシネート

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H315：皮膚刺激

  H318：重篤な眼の損傷

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

  P332+P313：皮膚刺激が生じた場合：医師の診断/手当てを受けるこ と。

ジオクチルソジウムスルホサクシネート 価格

MSDS Information

• Bis(2-ethylhexyl) sulfosuccinate sodium salt

ジオクチルソジウムスルホサクシネート 化学特性,用途語,生産方法

• 外観

  白色～わずかにうすい褐色, ペースト

• 定義

  本品は、スルホコハク酸と2-エチルヘキシルアルコールのジエステルのナトリウム塩で、次の化学式で表される。

• 溶解性

  水 (71g/L), 2-プロパノール, ベンゼンに可溶。水に溶ける。

• 無機性値/有機性値

  870/380

• 用途

  湿潤剤,洗浄剤,染色助剤,乳化重合助剤,農薬添加剤など

• 用途

  湿潤剤, 洗浄剤, 染色助剤, 乳化重合助剤, 農薬添加剤, 油中分散剤, ドライクリーニング助剤など

• 化粧品の成分用途

  界面活性助剤、洗浄剤

• 効能

  軟便化薬, 界面活性剤

• 化学的特性

  white solid, often supplied as an aqueous solution

• 使用

  Dioctyl sulfosuccinate sodium salt is a wetting and emulsifying agent that is slowly soluble in water, having a solubility of 1 g in 70 ml of water. It functions as a wetting agent in fumaric acid-containing powdered fruit drinks to help the acid dissolve in water. It is used as a stabilizing agent on gums at not more than 0.5% by weight of the gum. It is used as a flavor potentiator in canned milk where it improves and maintains the flavor of the sterilized milk during storage. It also functions as a processing aid in the manufacture of unrefined sugar. It is also termed sodium dioctylsulfosuccinate.

• 調製方法

  Maleic anhydride is treated with 2-ethylhexanol to produce dioctyl maleate, which is then reacted with sodium bisulfite.

• 一般的な説明

  Odorless colorless to white waxy solid. Sinks and mixes slowly with water.

• 空気と水の反応

  Mixes slowly with water.

• 反応プロフィール

  Docusate sodium causes foaming and spreading of water. Assists in putting out fires by water. [USCG, 1999].

• 健康ハザード

  Liquid is strong irritant to eye and may irritate skin by removing natural oils. Ingestion causes diarrhea and intestinal bloating.

• 火災危険

  Behavior in Fire: Causes foaming and spreading of water. Assists in putting out fires by water.

• 応用例（製薬）

  Docusate sodium and docusate salts are widely used as anionic surfactants in pharmaceutical formulations. Docusate sodium is mainly used in capsule and direct-compression tablet formulations to assist in wetting and dissolution.

• 安全性プロファイル

  Poison by intravenous route. Moderately toxic by ingestion and intraperitoneal routes. A skin and severe eye irritant. See also ESTERS. When heated to decomposition it emits toxic fumes of SOx and Na2O.

• 安全性

  Docusate salts are used in oral formulations as therapeutic agents for their fecal softening and laxative properties. As a laxative in adults, up to 500mg of docusate sodium is administered daily in divided doses; in children over 6 months old, up to 75 mg in divided doses is used. The quantity of docusate sodium used as an excipient in oral formulations should therefore be controlled to avoid unintended laxative effects. Adverse effects associated with docusate sodium include diarrhea, nausea, vomiting, abdominal cramps, and skin rashes. As with the chronic use of laxatives, the excessive use of docusate sodium may produce hypomagnesemia.
  Docusate salts are absorbed from the gastrointestinal tract and excreted in bile; they may cause alteration of the gastrointestinal epithelium. The gastrointestinal or hepatic absorption of other drugs may also be affected by docusate salts, enhancing activity and possibly toxicity. Docusate sodium should not be administered with mineral oil as it may increase the absorption of the oil.
  LD50 (mouse, IV): 0.06 g/kg
  LD50 (mouse, oral): 2.64 g/kg
  LD50 (rat, IP): 0.59 g/kg
  LD50 (rat, oral): 1.9 g/kg

• 貯蔵

  Docusate sodium is stable in the solid state when stored at room temperature. Dilute aqueous solutions of docusate sodium between pH 1–10 are stable at room temperature. However, at very low pH (<1) and very high pH (>10) docusate sodium solutions are subject to hydrolysis.
  The solid material is hygroscopic and should be stored in an airtight container in a cool, dry place.

• 純化方法

  Dissolve it in MeOH and the inorganic salts which precipitate are filtered off. Water is added and the solution is extracted several times with hexane. The residue is evaporated to one-fifth its original volume, *benzene is added and azeotropic distillation is continued until no water remains. The solvent is evaporated. The white residual solid is crushed and dried in vacuo over P2O5 for 48hours [El Seoud & Fendler J Chem Soc, Faraday Trans 1 71 452 1975]. [Beilstein 4 IV 114.] It solubilises major myelin trans membrane proteolipids, and forms reverse micelles in hydrocarbon solvents.

• 不和合性

  Electrolytes, e.g. 3% sodium chloride, added to aqueous solutions of docusate sodium can cause turbidity. However, docusate sodium possesses greater tolerance to calcium, magnesium, and other polyvalent ions than do some other surfactants. Docusate sodium is incompatible with acids at pH < 1 and with alkalis at pH > 10.

• 規制状況(Regulatory Status)

  GRAS listed. Included in the FDA Inactive Ingredients Database (IM injections; oral capsules, suspensions, and tablets; also topical formulations). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.

ジオクチルソジウムスルホサクシネート 上流と下流の製品情報

ジオクチルソジウムスルホサクシネート 生産企業

Global(869)Suppliers

ジオクチルソジウムスルホサクシネート スペクトルデータ(¹HNMR、¹³CNMR、IR1、Raman)

577-11-7, ジオクチルソジウムスルホサクシネート キーワード